Arca
Skip to content
Tools
Tools

Cerebral palsy

Drug research and approvals for cerebral palsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 341 studies of cerebral palsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 3 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 341
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 341 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 4

Phase 2 5

Phase 1 or earlier 2

How its trials ended

1,545 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 123 whose ending is known, 46% met their primary endpoint, 5% missed it and 49% stopped early.

  • Completed, result not reported82353%
  • Ongoing36323%
  • Status unknown23615%
  • Met its primary endpoint574%
  • Stopped: other or unclear372%
  • Stopped: enrollment or feasibility111%
  • Missed its primary endpoint6<1%
  • Stopped: lack of efficacy6<1%
  • Stopped: funding4<1%
  • Stopped: sponsor or business decision2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 11, 2018A randomized, double-blind, placebo-controlled study of TEV-50717 (deutetrabenazine) for the treatment of dyskinesia in cerebral palsy in children and…Deutetrabenazine (TEV-50717)Teva Pharmaceutical IndustriesClosed
Nov 28, 2017Metformin for motor and cognitive improvement in children with cerebral palsy: a feasibility studyMetforminBloorview Research InstituteClosed

FDA orphan designations

Approved first, then open designations, newest first
Jun 20, 2019BotoxBOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.Allergan, Inc.Approved
Jul 29, 2016DysportTreatment of lower limb spasticity in pediatric patients 2 years of age and olderIpsen Biopharmaceuticals, Inc.Approved
Jul 28, 2010CuvposaTo reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy)Shionogi, Inc.Approved
Jul 24, 2012Autologous umbilical cord bloodTreatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injuryDuke UniversityDesignated
Sep 26, 1994BaclofenTreatment of spasticity associated with cerebral palsy.Medtronic, Inc.Designated
Jan 30, 1992L-baclofenTreatment of intractable spasticity in children with cerebral palsy.Osmotica Pharmaceutical Corp.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.